Dr Vishal Navani
Affiliations
Clinical Assistant Professor
Cumming School of Medicine, Department of Oncology
Medical Oncologist
Arthur J.E. Child Comprehensive Cancer Centre
Member
Arnie Charbonneau Cancer Institute, Riddell Centre for Cancer Immunotherapy
Early Phase & Lung Cancer Clinical Trials Lead
Alberta Health Services
Contact information
Phone number
Office: 587-231-5096
Location
Arthur Child Cancer Centre: Physicians Offices Level 10
For media enquiries, contact
Kelly Johnston
Senior Communications Specialist
Please submit your media request here
Preferred method of communication
Admin Assistant - Subashree.Jayabalan@cancercarealberta.ca
T: 587-231-6304
F: 587-231-5077
Background
Educational Background
Master of Arts Medical Sciences, University of Oxford,
Bachelor of Medicine Bachelor of Surgery Imperial College London,
Member of the Royal Colleges of Physicians UK Internal Medicine,
Fellow of the Royal Australasian College of Physicians Medical Oncology,
Biography
Dr. Vishal Navani leads Calgary’s thoracic oncology clinical trials program and early-phase drug development unit, with a focus on translating innovative science into impactful cancer care. He has served as Principal Investigator on dozens of clinical trials across phases I–III, and sits on several national and international trial steering committees. He is focused on improving survival and quality of life outcomes for patient's living with thoracic & other malignancies via innovative drug development.
As Director of Glans‑Look Research, he oversees North America's largest real-world evidence (RWE) database in thoracic malignancies, advancing precision oncology and population-level insights. His research has attracted over $1.5 million in competitive grant funding, including a recent award from the Terry Fox Marathon of Hope Cancer Centres Network for his work in data science and patient reported outcomes. He has 82 published peer reviewed abstracts & manuscripts, with a H-Index of 13. His work has been published in high profile journals such as the Lancet Oncology, Journal of Clinical Oncology & JAMA Oncology, reflecting a commitment to high-impact, peer-reviewed research at the interface of clinical innovation and patient care.
He has won ASCO merit awards and authored pieces that have presented as Oral Presentations at the World Congress on Lung Cancer (Singapore 2024).
Dr. Navani is also a recognized thought leader in clinical evidence generation, contributing as a clinical expert to the Canadian Drug Agency (CDA) in support of national drug reimbursement and policy deliberations. In parallel, he collaborates closely with the life sciences sector, providing strategic guidance on clinical development, trial design, and real-world evidence integration. His academic work has been published in leading journals including Journal of Clinical Oncology, JAMA Oncology, and The Lancet Oncology,
He holds a MA (Honours) from Oxford, MBBS from London (Imperial College) & is board certified in Canada, Australia & the UK.
He sits on global & national advisory boards for major pharmaceutical sponsors, providing clinical development & medical affairs consultancy. He also provides clinical development advice & business development support to Novotech, a major CRO.
Research
Areas of Research
Participation in university strategic initiatives
Publications
Are you the profile owner?
Login to edit.